var data={"title":"Antithrombin, concentrate from human plasma and recombinant human: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Antithrombin, concentrate from human plasma and recombinant human: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5653?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=antithrombin-concentrate-from-human-plasma-and-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Antithrombin, concentrate from human plasma and recombinant human: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135930\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ATryn;</li>\n      <li>Thrombate III</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135931\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Antithrombin III NF;</li>\n      <li>Thrombate III&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135965\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Blood Product Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135933\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Antithrombin deficiency:</b>  IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>ATryn:</i></b> Prophylaxis of thrombosis during perioperative and peripartum procedures:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing is individualized based on pretherapy antithrombin (AT) activity levels. Therapy should begin before delivery or ~24 hours prior to surgery to obtain target AT activity levels. Dosing should be targeted to keep levels between 80% to 120% of normal. Loading dose should be given as a 15-minute infusion, followed by maintenance dose as a continuous infusion. Doses may be calculated based on the following formulas:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Surgical patients (nonpregnant):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: [(100 - baseline AT activity level) <b>divided</b> by 2.3] x body weight (kg) = units of antithrombin required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance infusion: [(100 - baseline AT activity level) <b>divided</b> by 10.2] x body weight (kg) = units of antithrombin required/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pregnant patients:</i> <b>Note:</b> Pregnant women undergoing surgical procedures (other than a Cesarean section) should also be dosed according to the formula below.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: [(100 - baseline AT activity level) <b>divided</b> by 1.3] x body weight (kg) = units of antithrombin required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance infusion: [(100 - baseline AT activity level) <b>divided</b> by 5.4] x body weight (kg) = units of antithrombin required/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dosing adjustments: Adjustments should be made based on AT activity levels to maintain levels between 80% to 120% of normal. Surgery or delivery may rapidly decrease AT levels; check AT level just after surgery or delivery. The first AT level should be obtained 2 hours after initiation and adjusted as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AT activity level &lt;80%: Increase dose by 30%; recheck AT level 2 hours after adjustment. Alternatively, an additional bolus dose (using loading dose formula) may be needed to rapidly restore AT levels. Calculate the additional bolus/loading dose using the last available AT activity result. After additional loading/bolus dose given, resume maintenance infusion at the same rate prior to bolus administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AT activity level 80% to 120%: No dosage adjustment needed; recheck AT level in 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AT activity level &gt;120%: Decrease dose by 30%; recheck AT level 2 hours after adjustment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Thrombate III:</i></b> Prophylaxis of thrombosis during surgical or obstetrical procedures or treatment of thromboembolism:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial loading dose: Dosing is individualized based on pretherapy antithrombin (AT) levels. The initial dose should raise AT levels to 120% and may be calculated based on the following formula:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">[(desired AT level % - baseline AT level %) x body weight (kg)] <b>divided</b> by 1.4 = units of antithrombin required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">For example, if a 70 kg adult patient had a baseline AT level of 57%, the initial dose would be:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">[(120% - 57%) x 70] divided by 1.4  = 3150 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: In general, subsequent dosing should be targeted to keep levels between 80% to 120% which may be achieved by administering 60% of the initial loading dose every 24 hours. Adjustments may be made by adjusting dose or interval. Maintain level within normal range for 2-8 days depending on type of procedure/situation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135934\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673198\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673199\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135914\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [human, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thrombate III: 500 units, 1000 units [contains heparin; exact potency labeled on each vial] </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [recombinant, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ATryn: 525 units, 1750 units [contains goat protein; exact potency labeled on each vial] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135900\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135917\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATryn: Infuse loading dose over 15 minutes, followed immediately by a continuous maintenance infusion. Administer reconstituted solution (without further dilution) or further diluted 100 units/mL solution. Filter during administration using an infusion set with a 0.22 micron in-line filter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombate III: Infuse over 10 to 20 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135916\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment and prevention of antithrombin deficiency:</b> Thrombate III: Treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism in patients with hereditary antithrombin (AT) deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of thromboembolic events:</b> ATryn: Prevention of perioperative and peripartum thromboembolic events in patients with hereditary antithrombin deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Not indicated for treatment of thromboembolic events in patients with hereditary antithrombin deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135907\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Liver enzyme abnormalities (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Hematuria (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Hemorrhage (&ge;5%), hematoma (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Infusion site reaction (&ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Hemarthrosis (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Blurred vision, chest tightness, chills, dizziness, dyspnea, fever, gastrointestinal fullness, muscle cramps, nausea, unpleasant taste, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135920\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATryn: Known hypersensitivity to goat and goat milk proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombate III: There are no contraindications listed in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to antithrombin, other anticoagulants, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135904\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including severe hypersensitivity reactions (eg, anaphylaxis), may occur; monitor closely during infusions. If hypersensitivity symptoms occur, discontinue immediately and institute supportive emergency care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Thrombate III: Thrombate III is AT collected from pooled human plasma (hpAT). A product of human plasma, it  may potentially contain infectious agents which could transmit disease, including the Creutzfeldt-Jakob Disease (CJD) agent; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections suspected to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: ATryn: Pharmacokinetics of the recombinant-derived product are influenced by pregnancy; distinct dosing recommendations are provided for pregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenic potential: ATryn: ATryn is AT manufactured using recombinant technology (rhAT). Recombinant human AT, also known as antithrombin alfa, is produced by transgenic goats expressing recombinant human AT in their milk, which is then collected and purified.  Antibodies against the recombinant antithrombin protein (or goat-milk protein) may theoretically develop and lead to an immunological reaction. A postmarketing patient registry has been created to monitor for antibody development; physicians are encouraged to enroll by contacting the manufacturer at 1-800-610-3776.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pharmacokinetic differences: Half-life and clearance differ significantly (~7 to 9 times) between the plasma-derived and the recombinant-derived product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298762\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135908\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8849&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: Antithrombin may enhance the anticoagulant effect of Heparin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): Antithrombin may enhance the anticoagulant effect of Heparins (Low Molecular Weight). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135910\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (Thrombate III); C (ATryn) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135922\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATryn: Adverse events were observed in some animal reproduction studies. An increased risk of adverse fetal or neonatal effects has not been observed in studies involving a limited number of pregnant women in their 3rd trimester. Pharmacokinetic studies in pregnant women using the recombinant product showed an increase in clearance and volume of distribution compared to nonpregnant patients. Therefore, distinct initial dosing recommendations are provided for pregnant women compared to nonpregnant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombate III: Adverse events were not observed in animal reproduction studies. Dosing recommendations do not differ for obstetric patients compared to nonpregnant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In patients with hereditary antithrombin (AT) deficiency, the risk of thromboembolic events such as VTE is increased; pregnancy and delivery further increase this risk. These products are specifically indicated for use in pregnant women with hereditary AT deficiency to decrease this risk, although use of other agents may be preferred (Bates, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thromboembolism has been reported in children of women with hereditary AT deficiency; AT concentrations in neonates of parents with hereditary AT deficiency should be measured immediately after birth. Plasma AT levels are typically lower in neonates and infants than in adults. Low plasma AT concentrations in neonates may not be indicative of deficiency; consultation with a coagulation expert is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9613966\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The antithrombin in Thrombate III is obtained from human donors; antithrombin is endogenous to human plasma. ATryn, which is manufactured using recombinant technology, has been detected in breast milk at concentrations of 1/50 to 1/100 of maternal serum concentrations (approximately equivalent to endogenous levels). The manufacturer recommends that caution be used if administered to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135923\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135912\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATryn: Monitor antithrombin activity level at baseline, 2 hours after initiation (and each dosage adjustment), and thereafter, at least once or twice daily when predictable levels achieved (between 80% and 120%). Monitor for hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombate III: Initially, monitor antithrombin (AT) at baseline, 20 minutes postinfusion (peak), 12 hours postinfusion, then preceding next infusion (trough level). Measure peak and trough AT levels with each subsequent dose until predictable levels achieved (between 80% and 120%). Some situations (eg, following surgery, hemorrhage or acute thrombosis, concurrent IV heparin administration), may require more frequent AT monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin (AT) concentrations in neonates of parents with hereditary AT deficiency should be measured immediately after birth.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135915\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Normal AT activity: ~1 unit/mL (healthy adults) (Rodgers, 2009). Treatment is used to maintain AT concentrations in plasma &gt;80% of normal; plasma AT concentrations are ~60% lower than normal in near term infants than levels observed in adults; premature infants may have  AT concentrations lower than other neonates.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135903\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antithrombin is the primary physiologic inhibitor of <i>in vivo</i> coagulation. It is an alpha<sub>2</sub>-globulin. Its principal actions are the inactivation of thrombin, plasmin, and other active serine proteases of coagulation, including factors IXa, Xa, XIa, and XIIa. The inactivation of proteases is a major step in the normal clotting process. The strong activation of clotting enzymes at the site of every bleeding injury facilitates fibrin formation and maintains normal hemostasis. Thrombosis in the circulation would be caused by active serine proteases if they were not inhibited by antithrombin after the localized clotting process (Schwartz, 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In patients with hereditary antithrombin (AT) deficiency, spontaneous thrombosis may occur due to decreased AT concentrations; therapy with human or recombinant AT restores functional AT activity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135919\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Plasma derived (Thrombate III):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Half-life elimination: Biologic: 2.5 days (immunologic assay); 3.8 days (functional AT assay). Half-life may be decreased following surgery, with hemorrhage, acute thrombosis, and/or during heparin administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recombinant derived (ATryn): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Distribution: V<sub>d</sub>: Pregnant women: 14.3 L; Nonpregnant patients: 7.7 L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Half-life elimination: 12-18 hours; surgery, childbirth hemorrhage, and/or concomitant heparin may shorten half-life </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322994\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thrombate III Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $4.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $4.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135924\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anbinex (AR, IL, PY, SG);</li>\n      <li>Anthrobin P (JP);</li>\n      <li>Antithrombin III (HK, KR);</li>\n      <li>Antithrombin III Immuno (HR, HU);</li>\n      <li>Atenativ (CZ, DE, DK, ES, FI, GR, HR, HU, IT, NL, NO, PL, SE, SK);</li>\n      <li>Atenativ 500 (AT, CH, HN);</li>\n      <li>Atenatyv (UA);</li>\n      <li>Atend (MX);</li>\n      <li>Atryn (CZ, DK, FR, GR, HR, HU, LT, LV, MT, NL, RO, SK);</li>\n      <li>ATryn (GB, PL, PT);</li>\n      <li>Kenketu Nonthron (JP);</li>\n      <li>Kybernin (HR, HU);</li>\n      <li>Kybernin P (BR, ES, ID);</li>\n      <li>Neuart (JP);</li>\n      <li>Octati (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Thrombate III (HK);</li>\n      <li>Thrombotrol-VF (AU, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antithrombin III (Human) [product monograph]. Mississauga, Ontario, Canada: Grifols Canada Ltd; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ATryn (antithrombin [recombinant] [prescribing information]. Framingham, MA: rEVO Biologics, Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012; 141; e691S-e736S. DOI: 10.1378/chest.11-2300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konkle BA, Bauer KA, Weinstein R, et al, &ldquo;Use of Recombinant Human Antithrombin in Patients With Congenital Antithrombin Deficiency Undergoing Surgical Procedures,&rdquo; <i>Transfusion</i>, 2003, 43(3):390-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/12675726/pubmed\" target=\"_blank\" id=\"12675726\">12675726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patnaik MM and Moll S, &ldquo;Inherited Antithrombin Deficiency: A Review,&rdquo; <i>Haemophilia</i>, 2008, 14(6):1229-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/19141163/pubmed\" target=\"_blank\" id=\"19141163\">19141163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. <i>Thromb Haemost</i>. 2009 May;101(5):806-812. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/19404531/pubmed\" target=\"_blank\" id=\"19404531\">19404531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. <i>Am J Med</i>. 1989, 87(3B):53S-60S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/2679072/pubmed\" target=\"_blank\" id=\"2679072\">2679072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thrombate III (antithrombin III) [prescribing information]. Research Triangle Park, NC: Grifols; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiede A, Tait RC, Shaffer DW, et al. Antithrombin Alfa in Hereditary Antithrombin Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations. <i>Thromb Haemost</i>. 2008, 99(3):616-622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/antithrombin-concentrate-from-human-plasma-and-recombinant-human-drug-information/abstract-text/18327412/pubmed\" target=\"_blank\" id=\"18327412\">18327412</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8849 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135930\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F135931\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135965\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135933\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135934\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673198\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673199\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135914\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135900\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135917\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135916\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135907\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135920\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135904\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298762\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135908\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F135910\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135922\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9613966\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F135923\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135912\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F135915\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135903\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F135919\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322994\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F135924\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8849|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=antithrombin-concentrate-from-human-plasma-and-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Antithrombin, concentrate from human plasma and recombinant human: Patient drug information</a></li></ul></div></div>","javascript":null}